Agreement Reached to Develop MMP-13 Inhibitors to Treat Myeloma

Home / Blog / Agreement Reached to Develop MMP-13 Inhibitors to Treat Myeloma
Agreement Reached to Develop MMP-13 Inhibitors to Treat Myeloma
May 03, 2022May 3, 2022
0

SteroTherapeutics has entered into an exclusive license agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation to develop matrix metalloproteinase 13 (MMP-13) inhibitors for treating multiple myeloma. “This partnership with Moffitt Cancer Center and the Research Institute of Florida Atlantic University will allow us to further develop this novel line of highly selective MMP-13 inhibitors for the treatment of multiple myeloma to fulfill our strategic intent to bring revolutionary breakthroughs and innovations that significantly…

You must be logged in to read/download the full post.